Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study

American Journal of Hematology

Volumn 86, Issue 9, 2011, Pages 796-800

  Welch, John S ^a   Klco, Jeffery M ^a   Gao, Feng ^a   Procknow, Elizabeth ^a   Uy, Geoffery L ^a   Stockerl Goldstein, Keith E ^a   Abboud, Camille N ^a   Westervelt, Peter ^a   DiPersio, John F ^a   Hassan, Anjum ^a   Cashen, Amanda F ^a   Vij, Ravi ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALANINE AMINOTRANSFERASE; ARSENIC TRIOXIDE; ASCORBIC ACID; MESSENGER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; BLOOD CELL COUNT; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENE EXPRESSION; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; IN VIVO STUDY; INCOMPLETE BLOOD COUNT RECOVERY; LETTER; MALE; MICROVASCULATURE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; SEPSIS; SIDE EFFECT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; ASCORBIC ACID; AZACITIDINE; BONE MARROW; BONE MARROW CELLS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOVASCULARIZATION, PATHOLOGIC; OXIDES; YOUNG ADULT;

EID: 80051801919     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22092     Document Type: Letter

References (30)

1. Musolino C, Sant'antonio E, Penna G, et al. Epigenetic therapy in myelodysplastic syndromes. Eur J Haematol 2010; 84: 463-473.
2. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 556-561.
3. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
4. Vey N, Bosly A, Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: A phase II multicenter study. J Clin Oncol 2006; 24: 2465-2471.
5. Schiller GJ, Slack J, Hainsworth JD, et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 2006; 24: 2456-2464.
6. Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, Gisslinger H. Arsenic trioxide and ascorbic acid: Synergy with potential implications for the treatment of acute myeloid leukaemia? Br J Haematol 2001; 112: 783-786.
7. Wang TS, Shu YF, Liu YC, et al. Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. Toxicology 1997; 121: 229-237.
8. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268-277.
9. Liu J, Chen H, Miller DS, et al. Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol 2001; 60: 302-309.
10. Gregus Z, Gyurasics A, Csanaky I. Biliary and urinary excretion of inorganic arsenic: Monomethylarsonous acid as a major biliary metabolite in rats. Toxicol Sci 2000; 56: 18-25.
11. Rodriguez-Ariza A, Lopez-Pedrera C, Aranda E, Barbarroja N. VEGF targeted therapy in acute myeloid leukemia. Crit Rev Oncol Hematol 2010;Epub Oct 27.
12. Alimoghaddam K, Shariftabrizi A, Tavangar SM, et al. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia. Leuk Lymphoma 2006; 47: 81-88.
13. Keith T, Araki Y, Ohyagi M, et al. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia. Br J Haematol 2007; 137: 206-215.
14. Douer D, Watkins K, Louie R, et al. Treatment of non-APL acute myelogenous leukemia with intravenous arsenic trioxide plus ascorbic acid. ASH Annual Meeting Abstracts; 2006. p 1959.
15. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52-57.
16. Kantarjian HM, O'Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: Comparison with historical experience. Cancer 2007; 109: 1133-1137.
17. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002; 8: 3658-3668.
18. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010; 116: 3751-3757.
19. Roboz GJ, Ritchie EK, Curcio T, et al. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer 2008; 113: 2504-2511.
20. Parmar S, Rundhaugen LM, Boehlke L, et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res 2004; 28: 909-919.
21. Madlambayan GJ, Meacham AM, Hosaka K, et al. Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 2010; 116: 1539-1547.
22. Stifter G, Heiss S, Gastl G, et al. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: Relationship to anemia and prognosis. Eur J Haematol 2005; 75: 485-491.
23. Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol 2009; 84: 599-600.
24. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007; 25: 3884-3891.
25. Sekeres MA, List AF, Cuthbertson D, et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010; 28: 2253-2258.
26. Atallah E, Cortes J, O'Brien S, et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood 2007; 110: 3547-3551.
27. Vij R, Ansstas G, Mosley JC, et al. Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant. Leuk Lymphoma 2010; 51: 1577-1579.
28. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008; 26: 317-325.
29. Payton JE, Grieselhuber NR, Chang LW, et al. High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest 2009; 119: 1714-1726.
30. de Jonge HJ, Fehrmann RS, de Bont ES, et al. Evidence based selection of housekeeping genes. PLoS One 2007; 2: e898.